GlassScriptPhysician profile
Jacqueline J Leventhal
NPI 1245494731
$1,439.23
in general payments reported to CMS, 2019-2025
20 companies · $73.68 in 2025
The $73.68 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.69 · 2020: $37.15 · 2021: $63.07 · 2022: $95.33 · 2023: $750 · 2024: $393 · 2025: $73.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $189 · Entertainment: $20.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.85 |
| Education | $188.99 |
| Entertainment | $20.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $377.23 | 2019-2024 | Ztlido |
| Astellas Pharma US INC | $205.42 | 2023 | Myrbetriq |
| Abbvie INC. | $154.89 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.46 | 2023-2025 | Relistor |
| Pfizer INC. | $69.82 | 2024-2025 | |
| Ibsa Pharma INC. | $67.39 | 2024 | Licart, Tirosint |
| Novo Nordisk INC | $66.55 | 2022-2024 | Wegovy |
| Arbor Pharmaceuticals, INC. | $66.19 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $62.37 | 2023-2024 | Horizant, Horizant |
| Xeris Pharmaceuticals, INC. | $41.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.60 | 2023 | Seglentis |
| Lilly USA, LLC | $29.70 | 2023 | Mounjaro |
| Redhill Biopharma INC. | $24.87 | 2023 | Movantik |
| Antares Pharma, INC. | $22.33 | 2024 | Xyosted |
| Optos, INC. | $20.15 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $19.05 | 2022 | |
| Intra-Sana Laboratories | $17.25 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boston Scientific Corporation | $16.11 | 2021 | |
| Gilead Sciences, INC. | $15.12 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Leventhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.